Lonza Group AG (LZAGF)
USD 740.0
(3.79%)
USD 740.0
(3.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.66 Billion CHF | 33.33% |
| 2022 | 1.24 Billion CHF | 6.94% |
| 2021 | 1.16 Billion CHF | -64.84% |
| 2020 | 3.31 Billion CHF | 1.22% |
| 2019 | 3.27 Billion CHF | -8.94% |
| 2018 | 3.6 Billion CHF | -4.41% |
| 2017 | 3.76 Billion CHF | 137.52% |
| 2016 | 1.58 Billion CHF | -4.52% |
| 2015 | 1.66 Billion CHF | -17.45% |
| 2014 | 2.01 Billion CHF | -7.49% |
| 2013 | 2.17 Billion CHF | -8.84% |
| 2012 | 2.38 Billion CHF | -12.76% |
| 2011 | 2.73 Billion CHF | 125.66% |
| 2010 | 1.21 Billion CHF | -10.49% |
| 2009 | 1.35 Billion CHF | 0.97% |
| 2008 | 1.34 Billion CHF | 0.0% |
| 2007 | 1.34 Billion CHF | 42.96% |
| 2006 | 938 Million CHF | -4.29% |
| 2005 | 980 Million CHF | -6.49% |
| 2004 | 1.04 Billion CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.39 Billion CHF | 0.0% |
| 2024 Q1 | 2.39 Billion CHF | 44.11% |
| 2023 Q4 | 1.66 Billion CHF | 2.21% |
| 2023 Q1 | 1.21 Billion CHF | -2.88% |
| 2023 FY | 1.66 Billion CHF | 33.33% |
| 2023 Q3 | 1.62 Billion CHF | 34.32% |
| 2023 Q2 | 1.21 Billion CHF | 0.0% |
| 2022 Q2 | 877 Million CHF | 0.0% |
| 2022 Q4 | 1.24 Billion CHF | 4.52% |
| 2022 FY | 1.24 Billion CHF | 6.94% |
| 2022 Q1 | 877 Million CHF | -24.85% |
| 2022 Q3 | 1.19 Billion CHF | 36.15% |
| 2021 FY | 1.16 Billion CHF | -64.84% |
| 2021 Q3 | 1.11 Billion CHF | -64.49% |
| 2021 Q2 | 3.14 Billion CHF | 0.0% |
| 2021 Q1 | 3.14 Billion CHF | -5.21% |
| 2021 Q4 | 1.16 Billion CHF | 4.48% |
| 2020 Q3 | 3.29 Billion CHF | 1.1% |
| 2020 Q2 | 3.25 Billion CHF | 0.0% |
| 2020 Q4 | 3.31 Billion CHF | 0.73% |
| 2020 Q1 | 3.25 Billion CHF | -0.61% |
| 2020 FY | 3.31 Billion CHF | 1.22% |
| 2019 Q1 | 3.37 Billion CHF | -6.39% |
| 2019 Q3 | 3.36 Billion CHF | -0.33% |
| 2019 FY | 3.27 Billion CHF | -8.94% |
| 2019 Q2 | 3.37 Billion CHF | 0.0% |
| 2019 Q4 | 3.27 Billion CHF | -2.41% |
| 2018 Q3 | 3.66 Billion CHF | -1.9% |
| 2018 Q1 | 3.73 Billion CHF | -0.96% |
| 2018 Q4 | 3.6 Billion CHF | -1.61% |
| 2018 FY | 3.6 Billion CHF | -4.41% |
| 2018 Q2 | 3.73 Billion CHF | 0.0% |
| 2017 Q4 | 3.76 Billion CHF | -2.05% |
| 2017 FY | 3.76 Billion CHF | 137.52% |
| 2017 Q2 | -1.47 Billion CHF | 0.0% |
| 2017 Q1 | -1.47 Billion CHF | -192.75% |
| 2017 Q3 | 3.84 Billion CHF | 361.45% |
| 2016 Q3 | 1.64 Billion CHF | 9.1% |
| 2016 Q1 | 1.5 Billion CHF | -9.33% |
| 2016 FY | 1.58 Billion CHF | -4.52% |
| 2016 Q2 | 1.5 Billion CHF | 0.0% |
| 2016 Q4 | 1.58 Billion CHF | -3.47% |
| 2015 Q1 | 1.84 Billion CHF | -8.4% |
| 2015 Q4 | 1.66 Billion CHF | -2.87% |
| 2015 Q2 | 1.84 Billion CHF | 0.0% |
| 2015 Q3 | 1.71 Billion CHF | -7.22% |
| 2015 FY | 1.66 Billion CHF | -17.45% |
| 2014 FY | 2.01 Billion CHF | -7.49% |
| 2014 Q1 | 2.18 Billion CHF | 0.46% |
| 2014 Q2 | 2.18 Billion CHF | 0.0% |
| 2014 Q3 | 2.08 Billion CHF | -4.49% |
| 2014 Q4 | 2.01 Billion CHF | -3.59% |
| 2013 Q4 | 2.17 Billion CHF | -1.85% |
| 2013 FY | 2.17 Billion CHF | -8.84% |
| 2013 Q3 | 2.21 Billion CHF | -11.89% |
| 2013 Q2 | 2.51 Billion CHF | 0.0% |
| 2013 Q1 | 2.51 Billion CHF | 5.41% |
| 2012 Q2 | 2.61 Billion CHF | 0.0% |
| 2012 FY | 2.38 Billion CHF | -12.76% |
| 2012 Q4 | 2.38 Billion CHF | 0.0% |
| 2011 FY | 2.73 Billion CHF | 125.66% |
| 2011 Q4 | 2.73 Billion CHF | 0.0% |
| 2011 Q2 | 1.29 Billion CHF | 0.0% |
| 2010 Q4 | 1.21 Billion CHF | 0.0% |
| 2010 Q2 | 1.29 Billion CHF | 0.0% |
| 2010 FY | 1.21 Billion CHF | -10.49% |
| 2009 Q4 | 1.35 Billion CHF | 0.0% |
| 2009 FY | 1.35 Billion CHF | 0.97% |
| 2009 Q2 | -231 Million CHF | 0.0% |
| 2008 Q4 | 1.34 Billion CHF | 0.0% |
| 2008 FY | 1.34 Billion CHF | 0.0% |
| 2007 FY | 1.34 Billion CHF | 42.96% |
| 2006 FY | 938 Million CHF | -4.29% |
| 2005 FY | 980 Million CHF | -6.49% |
| 2004 FY | 1.04 Billion CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | -75330.644% |
| Arrayit Corporation | 1.05 Million USD | -157538.455% |
| Atlantic International Corp. | 236.49 Thousand USD | -703505.981% |
| Biocept, Inc. | -788 Thousand USD | 211267.513% |
| Bioqual, Inc. | -12 Million USD | 13958.461% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -7317724.003% |
| DermTech, Inc. | 17.65 Million USD | -9326.16% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 390.659% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 22656.873% |
| iMD Companies, Inc. | 1.11 Million USD | -149015.434% |
| IDenta Corp. | 524.85 Thousand USD | -316941.757% |
| Interpace Biosciences, Inc. | 7.69 Million USD | -21527.242% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 6174038.854% |
| InVitro International | -313.14 Thousand USD | 531488.316% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | -106163.818% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 233380184.151% |
| Medical Imaging Corp. | 3.79 Million USD | -43794.184% |
| NovelStem International Corp. | 3.52 Million USD | -47152.108% |
| Optigenex Inc. | 8.93 Million USD | -18525.522% |
| PharmChem, Inc. | -1.49 Million USD | 111448.068% |
| Proteome Sciences plc | 14.57 Million USD | -11318.138% |
| Response Genetics, Inc | -13.08 Million USD | 12815.88% |
| Rennova Health, Inc. | 14.82 Million USD | -11120.592% |
| RushNet, Inc. | 4.8 Million USD | -34560.565% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -1227138.198% |
| Stella Diagnostics Inc. | 6.19 Million USD | -26768.79% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | -93152.686% |
| Todos Medical Ltd. | 38.31 Million USD | -4243.06% |